Dr. Jody Robert Tversky, MD

Dr. Tversky practices at Green Spring Station Endoscopy in Lutherville, Maryland.

Dr. Tversky's NPI, 1619014263, was assigned on January 31, 2007. Dr. Tversky holds Maryland license 5458.

Dr. Tversky's primary practice is Green Spring Station Endoscopy, at 10751 Falls Rd, Lutherville, MD 21093. The practice phone is (410) 583-2760.

Dr. Tversky's primary practice is Green Spring Station Endoscopy in Lutherville, Maryland. Dr. Tversky is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Tversky to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tversky practices, 4 sites in all. Vendor and product names are available with a free account.

Allergy is Dr. Tversky's primary specialty in the NPI Registry, under taxonomy code 207KA0200X. Dmand AI has Dr. Tversky's licenses on file in 5 states: Maryland, Connecticut, Florida, Hawaii and New York.

CMS data shows 33 Medicare services from Dr. Tversky across 1 procedure code in 2024, all of them office visits, for 49 Medicare patients. Medicare paid $3,883 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 49 Medicare patients who saw Dr. Tversky in 2024. The largest group is 65 to 74, with 27 patients. 67% of them have high cholesterol, and 65% have arthritis. 33% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tversky's median patient age at 44, with 63% women.

In 2024, Dr. Tversky wrote 78 Medicare Part D claims for 14 patients. 23% of them were for generic drugs. CMS names the drug for 46 of them, across 3 drugs with 11 or more claims each, at $116,420 in total drug cost. In 2023, CMS named 80 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Tversky for performance year 2024, reported as part of a group. CMS lists Dr. Tversky as offering telehealth.

Dmand AI links Dr. Tversky to 1 clinical trial. Conditions studied include Nasal Polyps and Polyps. Open Payments lists research payments to Dr. Tversky that name 1 trial.

CMS Open Payments shows 298 general payments to Dr. Tversky from 13 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 82% of the total. AstraZeneca Pharmaceuticals LP paid the most, $208,613. It also lists 2 research payments totaling $750 in 2022, naming 1 clinical trial.